Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gPNA D-NLS
- Development stage
- Preclinical
- Lead developer
- University of Connecticut
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
gPNA D-NLS is a synthetic oligonucleotide conjugate designed for targeted gene modulation in cancer. It consists of a gamma-modified peptide nucleic acid (gPNA) sequence targeting the c-Myc oncogene, conjugated to a nuclear localization signal (NLS) composed of D-amino acids (D-NLS). The D-amino acid modification enhances the proteolytic stability of the NLS in human serum compared to standard L-amino acid versions, while maintaining efficient nuclear transport via the importin alpha pathway. By targeting the c-Myc genomic DNA, the gPNA component achieves potent gene knockdown (approximately 90% in U2932 cells), leading to reduced protein levels and decreased cell viability. This technology is being developed at the University of Connecticut for potential applications in cancer treatment and other genetic modulation strategies.
- Other names
- gPNA D-NLS conjugategammaPNA-NLS construct
02
Targets
Nuclear import machineryMYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on gPNA D-NLS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gPNA D-NLS.